Source:http://linkedlifedata.com/resource/pubmed/id/15920912
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-5-30
|
| pubmed:abstractText |
Many resected patients with locally advanced head and neck cancer are found on pathological assessment to have high-risk features for recurrence. We thus performed a feasibility trial of post-operative radiotherapy with paclitaxel and carboplatin in high-risk carcinoma of the head and neck. All patients were planned for 6 cycles of weekly paclitaxel (40 mg/m2) and carboplatin (AUC=1) and concomitant radiotherapy, 60 Gy in 6 weeks. The most common side effect was grade 3 and 4 mucositis in 5/6 patients and g-tube placement in 4/6 patients. Five out of 6 patients remain alive without evidence of disease at a mean time of 19 months since completion of therapy. Our pilot study treated 6 postoperative patients. Since 4 of 6 enrolled patients were unable to complete the treatment as prescribed, we conclude that this regimen is not feasible. With an 83% grade 3 or 4 mucositis rate and 67% of patients enrolled requiring feeding tube placement, this regimen is not tolerable.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1120-009X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
237-41
|
| pubmed:dateRevised |
2009-8-4
|
| pubmed:meshHeading |
pubmed-meshheading:15920912-Adult,
pubmed-meshheading:15920912-Aged,
pubmed-meshheading:15920912-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15920912-Carboplatin,
pubmed-meshheading:15920912-Carcinoma, Squamous Cell,
pubmed-meshheading:15920912-Chemotherapy, Adjuvant,
pubmed-meshheading:15920912-Combined Modality Therapy,
pubmed-meshheading:15920912-Female,
pubmed-meshheading:15920912-Head and Neck Neoplasms,
pubmed-meshheading:15920912-Humans,
pubmed-meshheading:15920912-Male,
pubmed-meshheading:15920912-Middle Aged,
pubmed-meshheading:15920912-Neoplasm Recurrence, Local,
pubmed-meshheading:15920912-Neoplasm Staging,
pubmed-meshheading:15920912-Paclitaxel,
pubmed-meshheading:15920912-Pilot Projects,
pubmed-meshheading:15920912-Postoperative Care,
pubmed-meshheading:15920912-Prognosis,
pubmed-meshheading:15920912-Radiotherapy, Adjuvant,
pubmed-meshheading:15920912-Radiotherapy Dosage,
pubmed-meshheading:15920912-Risk Assessment,
pubmed-meshheading:15920912-Survival Analysis,
pubmed-meshheading:15920912-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer.
|
| pubmed:affiliation |
Department of Medicine, Division of Medical Oncology and Hematology, University of Illinois at Chicago, Chicago, Illinois, USA. mark.agulnik@uhn.on.ca
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|